Nunzio Antonelli
Director/Board Member chez STALLERGENES GREER
Profil
Nunzio Michele Antonelli is currently the Chief Executive Officer & Director at Stallergenes Canada, Inc. and a Director at Stallergenes Greer Ltd.
Previously, he held positions such as Managing Director & Executive Vice President at UCB Pharma SA (France), Executive VP-Biopharma Brands & Solutions at UCB SA, President at Stallergenes SA, Head-Molecular & Cell Biology Unit at Eni Rewind SpA, and SVP-Biotech Manufacturing & Process Development at Serono Pharmaceutical Research Institute.
He also served as a Senior Vice President at Merck Serono Ltd.
Mr. Antonelli holds a graduate degree from the University of Bari and Iowa State University.
Postes actifs de Nunzio Antonelli
| Sociétés | Poste | Début |
|---|---|---|
| STALLERGENES GREER | Director/Board Member | 12/12/2018 |
| Stallergenes Canada, Inc. | Chief Executive Officer | - |
Anciens postes connus de Nunzio Antonelli
| Sociétés | Poste | Fin |
|---|---|---|
Eni Rewind SpA
 Eni Rewind SpA Environmental ServicesIndustrial Services Eni Rewind produces and markets chemicals. The company is headquartered in Cardano Al Campo, Italy. | Corporate Officer/Principal | 01/01/1992 |
Merck Serono Ltd.
 Merck Serono Ltd. Miscellaneous Commercial ServicesCommercial Services Merck Serono Ltd. provides research and development services and manufactures medicinal drugs. The company is headquartered in Middlesex, the United Kingdom. | Corporate Officer/Principal | - |
| STALLERGENES | President | - |
UCB Pharma SA (France)
 UCB Pharma SA (France) Pharmaceuticals: MajorHealth Technology Part of UCB SA, UCB Pharma SA (France) specializes in allergic and respiratory diseases and disorders. The private company is based in Nanterre, France. | Chief Executive Officer | - |
| Serono Pharmaceutical Research Institute | Corporate Officer/Principal | - |
Formation de Nunzio Antonelli
| University of Bari | Graduate Degree |
| Iowa State University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| UCB | Health Technology |
| Entreprise privées | 7 |
|---|---|
Stallergenes SA
 Stallergenes SA Pharmaceuticals: MajorHealth Technology Stallergenes SA is an international biopharmaceutical company, which engages in the manufacture and sale of pharmaceutical products for the treatment of allergy-related respiratory diseases. The company operates through the Allergen Immunotherapy segment, which provides products and services for the desensitization of allergy-related respiratory conditions. Its products include a range of sublingual route and subcutaneous route products for the treatment of respiratory diseases such as rhino-conjunctivitis, rhinitis, and allergic asthma. Stallergenes was founded in 1962 and is headquartered in Antony, France. | Health Technology |
UCB Pharma SA (France)
UCB Pharma SA (France) Pharmaceuticals: MajorHealth Technology Part of UCB SA, UCB Pharma SA (France) specializes in allergic and respiratory diseases and disorders. The private company is based in Nanterre, France. | Health Technology |
| Serono Pharmaceutical Research Institute | |
Merck Serono Ltd.
Merck Serono Ltd. Miscellaneous Commercial ServicesCommercial Services Merck Serono Ltd. provides research and development services and manufactures medicinal drugs. The company is headquartered in Middlesex, the United Kingdom. | Commercial Services |
| Stallergenes Canada, Inc. | |
Eni Rewind SpA
Eni Rewind SpA Environmental ServicesIndustrial Services Eni Rewind produces and markets chemicals. The company is headquartered in Cardano Al Campo, Italy. | Industrial Services |
Stallergenes Greer Ltd.
 Stallergenes Greer Ltd. Pharmaceuticals: MajorHealth Technology Stallergenes Greer Ltd. is a healthcare company, which engages in the development and commercialization of allergy immunotherapy products and services. Its products include sublingual products, subcutaneous products, and veterinary products. The company was founded on December 6, 2013 and headquartered in London, the United Kingdom. | Health Technology |
